Clima social familiar y rendimiento académico de los estudiantes del segundo ciclo de la Facultad de Derecho y Ciencia Política de la Universidad Andina del Cusco, 2019 - II

El objetivo de la presente investigación es Determinar la relación entre el Clima Social familiar y el rendimiento académico de los estudiantes del segundo ciclo de la Facultad de Derecho y Ciencia política de la universidad Andina del Cusco 2019-II.; para desarrollar la investigación se ha utilizado el tipo de investigación básica, el enfoque cuantitativo, el diseño no experimental de corte transversal bajo y el alcance descriptivo correlacional, aplicado a 60 estudiantes que cursan la asignatura Taller de Redacción Jurídica; el instrumento aplicado para la variable Clima Social Familiar, se ha utilizado el Clima Social Familiar de Moss, la misma que está adaptada por Fernandez Balleseros y Sierra en la Universidad de Standfor. Cuya confiabilidad es de 0.84; para la segunda variable el instrumento de evaluación para medir el rendimiento académico, está amparado con las escalas de calificación de acuerdo a la Resolución 261- CU-2019-UAC, con el cual se valida el proceso evaluativo. La conclusión a la que se arriba es que se ha evidenciado que el Clima Social familiar de los estudiantes del segundo ciclo de la Facultad de Derecho y Ciencia política de la universidad Andina del Cusco 2019-II, de acuerdo al 60% presenta un clima social con tendencia a buena, el 31.7% con un nivel promedio que incide en el rendimiento académico donde el 48.3% con notas de 14 a 17 están aprobados y el 41.7% presentan notas desaprobatorias, demostrando con que existe una relación positiva alta de 0.791, probando la hipótesis planteadaThe objective of this research is to determine the relationship between the Family Social Climate and the academic performance of the students of the second cycle of the Faculty of Law and Political Science the University Andina the Cusco 2019-II .; To develop the research, the type of basic research, the quantitative approach, the non-experimental design with a low cross-sectional section and the correlational descriptive scope have been used, applied to 60 students who take the Legal Writing Workshop subject; In the instrument applied to the Family Social Climate variable, the Moss Family Social Climate has been used, which is adapted by Fernandez Balleseros y Sierra at the University of Standfor. Whose reliability is 0.84; For the second variable, the evaluation instrument to measure academic performance is covered by the rating scales according to Resolution 261-CU-2019-UAC, with which the evaluation process is validated. The conclusion reached is that it has been shown that the family Social Climate of the students of the second cycle of the Faculty of Law and Political Science the University Andina the Cusco 2019-II according to 60% presents a social climate with a tendency to good, 31.7 % with an average level that affects academic performance where 48.3% with grades from 14 to 17 are approved and 31.7% have disapproving grades, demonstrating that there is a high positive relationship of 0.791, testing the hypothesis raise

An integrated prognostic model for diffuse large B-cell lymphoma treated with immunochemotherapy

Diffuse large B-cell lymphoma (DLBCL), the most frequent non-Hodgkin's lymphoma subtype, is characterized by strong biological, morphological, and clinical heterogeneity, but patients are treated with immunochemotherapy in a relatively homogeneous way. Here, we have used a customized NanoString platform to analyze a series of 197 homogeneously treated DLBCL cases. The platform includes the most relevant genes or signatures known to be useful for predicting response to R-CHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone) in DLBCL cases. We generated a risk score that combines the International Prognostic Index with cell of origin and double expression of MYC/BCL2, and stratified the series into three groups, yielding hazard ratios from 0.15 to 5.49 for overall survival, and from 0.17 to 5.04 for progression-free survival. Group differences were highly significant (p < 0.0001), and the scoring system was applicable to younger patients (<60 years of age) and patients with advanced or localized stages of the disease. Results were validated in an independent dataset from 166 DLBCL patients treated in two distinct clinical trials. This risk score combines clinical and biological data in a model that can be used to integrate biological variables into the prognostic models for DLBCL cases.Funding information: GILEAD, Grant/Award Numbers: PIE15/0081, PI16/01294, PI17/2172, PI17/00272, PI19/00715, GL18/00019; Asociación Española Contra el Cáncer, Grant/Award Number: PROYE18054PIRI; Instituto de Salud Carlos III, Grant/Award Number: PT17/0015/0024; Xarxa de Bancs de Tumors de Catalunya; Biobank do Complexo Hospitalario Universitario de Santiago de Compostela, Grant/Award Number: PT17/0015/0002; Hospital Universitario Virgen del Rocío-Instituto de Biomedicina de Sevilla Biobank, Grant/Award Number: PT17/0015/0041; Valdecilla Biobank, Grant/Award Number: PT17/0015/0019;MD Anderson Biobank, Grant/Award Number: PT17/0015/0008; AIRC (Italian Association for Cancer Research, Milan, Italy), Grant/Award Number: 5×1000 n. 21198; Marie Skłodowska-Curie Individual Fellowship, Grant/Award Number: 882597; CIBERONC, Grant/Award Number: CB16/12/00291; Comunidad Autonoma de MadridDLBCLGene expressionImmunochemotherapyDiffuse large B-cell lymphomaPrognosi

An integrated prognostic model for diffuse large B‐cell lymphoma treated with immunochemotherapy

Abstract Diffuse large B‐cell lymphoma (DLBCL), the most frequent non‐Hodgkin's lymphoma subtype, is characterized by strong biological, morphological, and clinical heterogeneity, but patients are treated with immunochemotherapy in a relatively homogeneous way. Here, we have used a customized NanoString platform to analyze a series of 197 homogeneously treated DLBCL cases. The platform includes the most relevant genes or signatures known to be useful for predicting response to R‐CHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone) in DLBCL cases. We generated a risk score that combines the International Prognostic Index with cell of origin and double expression of MYC/BCL2, and stratified the series into three groups, yielding hazard ratios from 0.15 to 5.49 for overall survival, and from 0.17 to 5.04 for progression‐free survival. Group differences were highly significant (p < 0.0001), and the scoring system was applicable to younger patients (<60 years of age) and patients with advanced or localized stages of the disease. Results were validated in an independent dataset from 166 DLBCL patients treated in two distinct clinical trials. This risk score combines clinical and biological data in a model that can be used to integrate biological variables into the prognostic models for DLBCL cases